References
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300. https://doi.org/10.3322/caac.20073
- Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988;96:440-7.
- Putila J, Remick SC, Guo NL. Combining clinical, pathological, and demographic factors refines prognosis of lung cancer: a population-based study. PLoS One 2011;6:e17493. https://doi.org/10.1371/journal.pone.0017493
- Dai J, Jin G, Dong J, Chen Y, Xu L, Hu Z, et al. Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival. J Thorac Oncol 2010;5:1748-54. https://doi.org/10.1097/JTO.0b013e3181f18cb9
- Togashi Y, Masago K, Fujita S, Kim YH, Sakamori Y, Hatachi Y, et al. Association of the transforming growth factor ss1 promoter polymorphism, C-509T, with smoking status and survival in advanced non-small cell lung cancer. Oncol Rep 2011;25:377-82.
- Minamiya Y, Miura M, Hinai Y, Saito H, Ito M, Ono T, et al. Transforming growth factor-beta1 29T>C genetic polymorphism is associated with lymph node metastasis in patients with adenocarcinoma of the lung. Tumour Biol 2010;31:437- 41. https://doi.org/10.1007/s13277-010-0052-6
- Niu X, Chen Z, Shen S, Liu Y, Zhou D, Zhang J, et al. Association of the CHRNA3 locus with lung cancer risk and prognosis in Chinese Han population. J Thorac Oncol 2010;5:658-66. https://doi.org/10.1097/JTO.0b013e3181d5e447
- Horgan AM, Yang B, Azad AK, Amir E, John T, Cescon DW, et al. Pharmacogenetic and germline prognostic markers of lung cancer. J Thorac Oncol 2011;6:296-304. https://doi.org/10.1097/JTO.0b013e3181ffe909
- Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000;57:25-40. https://doi.org/10.1007/s000180050497
- Werle B, Kotzsch M, Lah TT, Kos J, Gabrijelcic-Geiger D, Spiess E, et al. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res 2004;24:4147-61.
- Pedersen H, Grondahl-Hansen J, Francis D, Osterlind K, Hansen HH, Dano K, et al. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 1994;54:120-3.
- Di Bernardo MC, Matakidou A, Eisen T, Houlston RS; GELCAPS Consortium. Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis. Lung Cancer 2009;65:237-41. https://doi.org/10.1016/j.lungcan.2008.11.012
- Kutz SM, Higgins CE, Samarakoon R, Higgins SP, Allen RR, Qi L, et al. TGF-beta 1-induced PAI-1 expression is E box/ USF-dependent and requires EGFR signaling. Exp Cell Res 2006;312:1093-105. https://doi.org/10.1016/j.yexcr.2005.12.027
- Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57. https://doi.org/10.1056/NEJMoa0810699
- Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7. https://doi.org/10.1378/chest.111.6.1710
- Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001;18:1059-68. https://doi.org/10.1183/09031936.01.00275301
- Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-501. https://doi.org/10.1200/JCO.2005.01.388
- Samarakoon R, Higgins CE, Higgins SP, Higgins PJ. TGFbeta1- induced expression of the poor prognosis SERPINE1/ PAI-1 gene requires EGFR signaling: a new target for anti- EGFR therapy. J Oncol 2009;2009:342391.
- Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 2004;37:541-8. https://doi.org/10.1016/j.clinbiochem.2004.05.013
- Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000;60:636-43.
- Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 1999;79:1746-51. https://doi.org/10.1038/sj.bjc.6690278
- Heiss MM, Allgayer H, Gruetzner KU, Babic R, Jauch KW, Schildberg FW. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer. Ann Surg 1997;226:736-44. https://doi.org/10.1097/00000658-199712000-00010
- Nielsen HJ, Christensen IJ, Sorensen S, Moesgaard F, Brunner N. Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol 2000;7:617-23. https://doi.org/10.1007/BF02725342
- Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Kolk A, et al. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity: clinical relevance and prognostic value. J Craniomaxillofac Surg 2005;33:191-6. https://doi.org/10.1016/j.jcms.2004.12.005
- Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004;10:39-49. https://doi.org/10.2174/1381612043453559
- Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: changing views. J Pathol 2008;214:283-93. https://doi.org/10.1002/path.2282
- Binder BR, Mihaly J. The plasminogen activator inhibitor "paradox" in cancer. Immunol Lett 2008;118:116-24. https://doi.org/10.1016/j.imlet.2008.03.017
- Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH, et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994;54:4671-5.
- Salden M, Splinter TA, Peters HA, Look MP, Timmermans M, van Meerbeeck JP, et al. The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. Ann Oncol 2000;11:327-32. https://doi.org/10.1023/A:1008312801800
- Offersen BV, Pfeiffer P, Andreasen P, Overgaard J. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis. Lung Cancer 2007;56:43-50. https://doi.org/10.1016/j.lungcan.2006.11.018
- Nielsen LS, Andreasen PA, Grondahl-Hansen J, Huang JY, Kristensen P, Dano K. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells: inhibitor neutralization and onestep affinity purification. Thromb Haemost 1986;55:206-12.
- Bouchard L, Mauriege P, Vohl MC, Bouchard C, Perusse L. Plasminogen-activator inhibitor-1 polymorphisms are associated with obesity and fat distribution in the Quebec Family Study: evidence of interactions with menopause. Menopause 2005;12:136-43. https://doi.org/10.1097/00042192-200512020-00006
- French D, Hamilton LH, Mattano LA Jr, Sather HN, Devidas M, Nachman JB, et al. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008;111:4496-9. https://doi.org/10.1182/blood-2007-11-123885
- Tsai SJ, Hong CJ, Liou YJ, Yu YW, Chen TJ. Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response. Pharmacogenet Genomics 2008;18:869-75. https://doi.org/10.1097/FPC.0b013e328308bbc0
- Kathiresan S, Gabriel SB, Yang Q, Lochner AL, Larson MG, Levy D, et al. Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels. Circulation 2005;112:1728-35. https://doi.org/10.1161/CIRCULATIONAHA.105.547836